Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-30 01:14:43 - browse：8344

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： 'CMA Fest' 2023: How to watch, who is performing and more

focus

WSS

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

A new crop of companies is reshaping the health data economy

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Dems pitch expanding Medicare power to negotiate drug prices

Will the FTC rein in IQVIA's health data empire?

focus

Wikipedia

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

A new ‘biological computer' targets cancer while sparing healthy cells

How to save PrEP access — and even expand it

After a decade, new Gardasil ad campaign gets it (mostly) right

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Trump demands the U.S. pay no more for drugs than other countries … again

How a Boston hospital is priming medical residents to use GPT

United colonoscopy coverage change 'may cost lives,' doctors say

US jobless claims fall again as labor market continues to flash strength

explore

Device maker Teleflex to acquire urology company for $600M

When a patient nears the end, a feared therapy can comfort

Why patients can’t get everything they want on drug pricing

What to watch for from Zogenix and Amicus clinical trials

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Hormonal contraceptives don’t actually treat endometriosis

leisure time

focus

entertainment

focus